TPI to Hold 2011 Shareholder Annual Meeting on April 11, 2012 in New York City
CHENGDU, China, Jan. 24, 2012 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today announced that the Company's 2011 Annual Shareholder Meeting will be held at Floor 20, 17 State Street, New York, NY 10004 on Wednesday, April 11, 2012, at 10:00 am (EST).
TPI's Board of Directors has established Monday, February 13, 2012, as the record date for determining the stockholders entitled to vote at the Annual Meeting.
Stockholder proposals must be received no later than Friday, February 17, 2012, in order to be considered for inclusion in the Company's proxy statement or to be presented at the Annual Meeting. Stockholder proposals should be mailed to Hunter Taubman Weiss LLP, c/o Tianyin Pharmaceutical Co., Inc, 17 State Street, Floor 20, New York, NY 10004.
Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.
For more information about TPI, please visit: http://www.tianyinpharma.com.
Safe Harbor Statement
The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.
Tel: +86-28-8551-6696 (Chengdu, China)
23rd Floor, Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
SOURCE Tianyin Pharmaceutical Co., Inc.
More by this Source
TPI Auditor Change Updates
Oct 15, 2013, 00:23 ET
TPI Facility Received GMP Renewal by CFDA
Aug 15, 2013, 12:59 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.